Washington: According to the U.S.
Buy Noida Toll Bridge with a stop loss below Rs 55 for targets of Rs 63 and Rs 67. 
Washington, Dec 5: NASA's Hubble SpacGeojit Financial Services has reiterated its BUY recommendation on Sagar Cements Limited, setting a 12-month target price of Rs.
News in Focus
Featured, India Business, Analyst View, Cement Sector, Geojit Financial Services, India, Sagar Cements
ICICI Direct has reiterated a BUY rating on Lemon Tree Hotels Ltd. with a revised target price of Rs.160, implying a 19% upside from the current market price of Rs.134.
Sri Lanka enter their 2026 Men’s T20 World Cup group clash against Oman as overwhelming favourites, backed by a rich tournament legacy, deeper squad resources, and a winning start to their campaign
Featured, India Business, Analyst View, Stock Markets, BOB Capital Markets, India, Jubilant FoodWorks, Retail Sector
BOB Capital Markets has reiterated its BUY call on Jubilant FoodWorks (JUBI IN) with a revised target price of Rs 676, implying an upside of approximately 22% from the current market price of Rs 55
ICICI Direct has reiterated its BUY recommendation on Arvind SmartSpaces, setting a revised 12-month target price of Rs 750, implying a 29% upside from the current market price of Rs 584.
ICICI Securities has reiterated a BUY call on Titan Company, assigning a 12-month target price of Rs4,980 against the current market price of Rs4,
Main Regional Stories
Labour is one of the most unpredictable inputs on Indian farms. During peak windows (land preparation before a shower, sowing in a narrow slot, or fast harvesting), finding enough hands can be harder than arranging seed or fertiliser.
Featured, India Business, Analyst View, Geojit Financial Services, India, LTIMindtree, Technology Sector
Geojit Investments Ltd has reiterated a HOLD recommendation on LTIMindtree Ltd, revising its 12-month target price to Rs.
Geojit Investments has reaffirmed its HOLD rating on HDFC Bank Limited, citing resilient earnings momentum, improving asset quality, and disciplined cost management, while flagging concerns around the bank’s elevated loan-to-deposit ratio.
Featured, India Business, Analyst View, Stock Markets, HealthCare, India, Max Healthcare, Prabhudas Lilladher
Max Healthcare Institute reported a subdued Q3FY26, with EBITDA growth constrained by seasonal softness, temporary operational disruptions, and pre-commissioning costs linked to capacity expansion.
